BCMA72-80
CAS No. 2293841-58-2
BCMA72-80( —— )
Catalog No. M30504 CAS No. 2293841-58-2
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with a strong affinity to HLA-A2. It is used to used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameBCMA72-80
-
NoteResearch use only, not for human use.
-
Brief DescriptionBCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with a strong affinity to HLA-A2. It is used to used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors.
-
DescriptionBCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with a strong affinity to HLA-A2. It is used to used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2293841-58-2
-
Formula Weight1196.55
-
Molecular FormulaC59H97N13O11S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:Tyr-Leu-Met-Phe-Leu-Leu-Arg-Lys-Ile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Bae J, et al. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 Mar 12.
molnova catalog
related products
-
N6-(p-Hydroxypheneth...
N6-(p-Hydroxyphenethyl)-Adenosine) is an adenosine analogue.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
-
Cannabichromenic aci...
Cannabichromenic acid is a new antibiotic active against gram-positive bacteria, including MRSA.